Healthcare >> CEO Interviews >> October 29, 2004
DAVID W. MOSKOWITZ, MD, MA Chief Medical Officer of GenoMed. Dr.
Moskowitz majored in Chemistry (summa cum laude) at Harvard College,
Biochemistry (first class honours) at Merton College, Oxford, and
received an MD (cum laude) from the Harvard-MIT Division in Health
Sciences and Technology (Harvard Medical School). He trained for 7 years
in Internal Medicine and Nephrology at Washington University School of
Medicine in St. Louis, before spending 11 years on the faculty of St.
Louis University School of Medicine. From 1994 to 1997, Dr. Moskowitz
experienced first hand the clinical effectiveness of knowing a disease-
associated gene (the angiotensin converting enzyme, or ACE, gene). Dr.
Moskowitz is a pioneer in the field of medical genomics, and has been
recognized for his ground breaking treatment of diseases associated with
the angiotensin I-converting enzyme, such as chronic renal failure due
to hypertension or type II diabetes. Profile
TWST: Could you give us a little history and a quick overview ofGenoMed?
Dr. Moskowitz: We're a medical genomics company. Our goal is to find
disease-causing genes and then change what's done